TABLE 4.

Hemodynamic and vascular measures at baseline and 2 h after non-EPs consumed a 40-mg equol supplement (SE5-OH) and EPs consumed a matched placebo (containing CMC)¹

	EP phenotype
	Non-EPs		EPs		P
	0 h	0–2 h	0 h	0–2 h
RHI	2.78 ± 0.14	0.40 ± 0.23	2.71 ± 0.17	−0.09 ± 0.23	0.16
Diastolic BP, mm Hg	80 ± 2	1 ± 2	78 ± 2	0 ± 2	0.76
Systolic BP, mm Hg	134 ± 3	1 ± 2	125 ± 4	1 ± 2	0.94
CO, L/min	4.60 ± 0.25	−0.17 ± 0.17	3.93 ± 0.27	0.03 ± 0.17	0.44
AI, %	24 ± 1	0 ± 1	24 ± 1	−1 ± 1	0.19
cfPWV, m/s	9.8 ± 0.3	0.1 ± 0.2	10.2 ± 0.4	−0.5 ± 0.2	0.13

¹Baseline values are means ± SEMs; values for 0–2 h are adjusted means ± SEMs, with age used as a covariate. n = 14/group. Differences in study endpoints between interventions were analyzed by using general linear model (univariate analysis). AI, augmentation index; BP, blood pressure; cfPWV, carotid-femoral pulse-wave velocity; CMC, carboxy-methyl cellulose; CO, cardiac output; EP, equol producer; RHI, reactive hyperemia index.